347 related articles for article (PubMed ID: 26664449)
21. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
[TBL] [Abstract][Full Text] [Related]
22. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management.
Shah SA; Gupta AS; Kumar P
J Cancer Res Ther; 2021; 17(1):1-9. PubMed ID: 33723124
[TBL] [Abstract][Full Text] [Related]
24. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
25. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
Gertsch J; Raduner S; Altmann KH
J Recept Signal Transduct Res; 2006; 26(5-6):709-30. PubMed ID: 17118807
[TBL] [Abstract][Full Text] [Related]
26. Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors.
Yang Y; Vyawahare R; Lewis-Bakker M; Clarke HA; Wong AHC; Kotra LP
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751516
[TBL] [Abstract][Full Text] [Related]
27. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
28. Absence of Entourage: Terpenoids Commonly Found in
Santiago M; Sachdev S; Arnold JC; McGregor IS; Connor M
Cannabis Cannabinoid Res; 2019; 4(3):165-176. PubMed ID: 31559333
[No Abstract] [Full Text] [Related]
29. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
30. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
Di Marzo V
Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
[TBL] [Abstract][Full Text] [Related]
31. Endocannabinoid-Binding Receptors as Drug Targets.
Gómez-Cañas M; Rodríguez-Cueto C; Satta V; Hernández-Fisac I; Navarro E; Fernández-Ruiz J
Methods Mol Biol; 2023; 2576():67-94. PubMed ID: 36152178
[TBL] [Abstract][Full Text] [Related]
32. The synthetic CB
Coronado-Álvarez A; Romero-Cordero K; Macías-Triana L; Tatum-Kuri A; Vera-Barrón A; Budde H; Machado S; Yamamoto T; Imperatori C; Murillo-Rodríguez E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110301. PubMed ID: 33741446
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
34. Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from
Nigro E; Formato M; Crescente G; Daniele A
Molecules; 2021 May; 26(9):. PubMed ID: 34063214
[No Abstract] [Full Text] [Related]
35. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
36. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
38. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.
Galal AM; Slade D; Gul W; El-Alfy AT; Ferreira D; Elsohly MA
Recent Pat CNS Drug Discov; 2009 Jun; 4(2):112-36. PubMed ID: 19519560
[TBL] [Abstract][Full Text] [Related]
39. [New targeted compounds-biosynthesis of phytocannabinoids].
Gao P; Chen Y; Ke C; Yang X; Huang J
Sheng Wu Gong Cheng Xue Bao; 2021 Jun; 37(6):1968-1985. PubMed ID: 34227288
[TBL] [Abstract][Full Text] [Related]
40. Pure Δ
Romano B; Pagano E; Orlando P; Capasso R; Cascio MG; Pertwee R; Marzo VD; Izzo AA; Borrelli F
Pharmacol Res; 2016 Nov; 113(Pt A):199-208. PubMed ID: 27498155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
